Moreover, a comprehensive evaluation of clinical risk factors, including age, gender, body mass index, SBP, FBG, and smoking, along with serum biomarkers like AOPP, IL-6, and GDF15, may have a more profound impact on assessing arteriosclerosis in patients with OSA. This evidence concerns the gene GDF15 and arteriosclerosis.